| Keegan Hackman, LMSW | |
|
28 Crescent St, Middletown, CT 06457-3654 | |
| (860) 358-3423 | |
| Not Available |
| Full Name | Keegan Hackman |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 28 Crescent St, Middletown, Connecticut |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083075840 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | (* (Not Available)) | Primary |
| Entity Name | New Vitae Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609923622 PECOS PAC ID: 0840278222 Enrollment ID: O20040712000932 |
News Archive
The protocol used to treat the first known survivor of rabies without prior vaccination is published in the June 16, 2005, issue of the New England Journal of Medicine. It is hoped that this approach can be replicated, tested, and provide a guide for treating this fatal condition, especially in parts of the world where the incidence of rabies is rampant.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.
Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects and in patients with dementia, including Alzheimer's disease.
Impaired sense of smell occurs in the earliest stages of Parkinson's disease (PD) and there is mounting evidence that it may precede motor symptoms by several years, although no large-scale studies had confirmed this.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Keegan Hackman, LMSW 28 Crescent St, Middletown, CT 06457-3654 Ph: () - | Keegan Hackman, LMSW 28 Crescent St, Middletown, CT 06457-3654 Ph: (860) 358-3423 |
News Archive
The protocol used to treat the first known survivor of rabies without prior vaccination is published in the June 16, 2005, issue of the New England Journal of Medicine. It is hoped that this approach can be replicated, tested, and provide a guide for treating this fatal condition, especially in parts of the world where the incidence of rabies is rampant.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.
Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects and in patients with dementia, including Alzheimer's disease.
Impaired sense of smell occurs in the earliest stages of Parkinson's disease (PD) and there is mounting evidence that it may precede motor symptoms by several years, although no large-scale studies had confirmed this.
› Verified 3 days ago
Rebecca Rotondo, LMSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 230 Main Street Extension, Act Team, Gilead Community Services, Middletown, CT 06457 Phone: 860-343-5300 | |
Ellen B Koch, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: River Valley Services, Dutton Home Silver St, Middletown, CT 06457 Phone: 860-262-5358 Fax: 860-262-5356 | |
Vanessa M Cardella, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 267 William St, Middletown, CT 06457 Phone: 860-834-1018 | |
Amanda L Wolf, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 1 Macdonough Pl, Middletown, CT 06457 Phone: 860-358-3437 | |
Rachel U Manemeit, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: Dutton Home Silver St, River Valley Services, Middletown, CT 06457 Phone: 860-262-5358 Fax: 860-262-5356 | |
Mr. Walter Livingston Miller, LCSW LADC NCGC II Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: Problem Gambling Services 2 Vance Drive Russell Hall, Connecticut Valley Hospital, Middletown, CT 06457 Phone: 860-344-2244 Fax: 860-344-2360 | |
Howard W Labrecque, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 28 Crescent St, Middletown, CT 06457 Phone: 860-344-6394 Fax: 860-344-6748 |